NCT Number: NCT02250573
An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery
The main objectives of this study were to investigate the safety and efficacy of Replenine®-VF administered in appropriate dosage by bolus infusion to prevent bleeding and achieve haemostasis in subjects with haemophilia B undergoing surgery.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Samodzielny Publiczny Zaklad Opieki Zdrowotnej nad Matka I Dzieckiem, ul. Krysiewicza 7/8., Poznan, Poland
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subjects with moderate to severe haemophilia B undergoing major surgery requiring an in-patient stay of generally 5 to 10 days.
Exclusion criteria
-
Treatment and study plan
Primary outcomes
-
Incremental recovery for Factor IX
Time frame: 90 min post-dose
Incremental recovery is defined as peak rise in plasma Factor IX levels divided by Factor IX dose in IU/KG
Sponsors and collaborators
Lead sponsor
Bio Products Laboratory
Other
Registry information
Official study title
An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery.
Important dates
- Study start
- 2005
- Primary completion
- 2006
- First posted
- Sep 26, 2014
- Registry last updated
- Feb 22, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Post-marketing Surveillance (Use Result Surveillance) With Refixia®
NCT03875547
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Søborg, Denmark
View Trial DetailsA Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
NCT05365217
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, Beijing Municipality, China
View Trial DetailsSafety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
NCT02141074
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Long Beach, California, United States
View Trial DetailsSafety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
NCT01467427
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Los Angeles, California, United States
View Trial Details